Pradžia › Atopinis dermatitas (egzema) › Arkansas
Atopinis dermatitas (egzema) klinikiniai tyrimai Arkansas
8 tyrimai dėl Atopinis dermatitas (egzema) ieško dalyvių vietose Arkansas.
Miestai Arkansas
Oficialus tyrimo tekstas (anglų kalba)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fort Smith
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-09-28 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Hot Springs
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Arkansas Research Trials, North Little Rock
Renkami dalyviai3 fazė
Amžius nuo 2 iki 11 · Visoms lytims · Atnaujinta 2026-09-25 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Dermatology Trial Associates, Inc, Bryant
Renkami dalyviai2 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Applied Research Center and Wellness Clinic /ID# 268547, Little Rock
Renkami dalyviai3 fazė
Amžius nuo 2 iki 11 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, North Little Rock
Renkami dalyviai3 fazė
6 Months – 11 Years · Visoms lytims · Atnaujinta 2026-07-07 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville
Renkami dalyviai3 fazė
Amžius nuo 18 iki 63 · Visoms lytims · Atnaujinta 2026-07-06 · NCT06389136A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
- Arkansas Research Trials, North Little Rock
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-19 · NCT06055361Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.